Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. [electronic resource]
Producer: 20171109Description: 1286-1294 p. digitalISSN:- 1532-1827
- Adenocarcinoma -- pathology
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Camptothecin -- administration & dosage
- Capecitabine -- administration & dosage
- Cetuximab -- administration & dosage
- Chemoradiotherapy
- Class I Phosphatidylinositol 3-Kinases -- genetics
- Combined Modality Therapy
- Female
- Follow-Up Studies
- GTP Phosphohydrolases -- genetics
- Humans
- Irinotecan
- Male
- Membrane Proteins -- genetics
- Middle Aged
- Mutation
- Neoplasm Staging
- Postoperative Care
- Prognosis
- Prospective Studies
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras) -- genetics
- Rectal Neoplasms -- pathology
- Retrospective Studies
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.